Novel Psychoactive Substance Testing

Novel Psychoactive Substance Testing

Aegis is pleased to offer industry-leading testing options to allow providers the opportunity to more completely understand an individual’s substance use pattern, and facilitate more informed care.

Novel psychoactive substances (NPS) are compounds designed to mimic the effects of prescription drugs, evade detection by typical drug testing methodologies, and avoid regulation. NPS can be described by numerous terms, including legal highs or research chemicals labelled ‘not for human use’.

  • NPS markets rapidly change in response to regulation from US and other international agencies.
  • NPS may potentiate drug interactions with prescription medications, leading to unintended overdoses.
  • Individuals are exposed to fentanyl, designer opioids and benzodiazepines knowingly, or unknowingly through counterfeit prescription drugs intended to mimic common drugs such as oxycodone, hydrocodone and alprazolam, among others.

Ordering Information
Aegis' NPS testing is available for urine specimens as an add-on by drug class. Providers may choose one or multiple classes based on medical necessity. 

Novel Psychoactive Substance Testing
The elements of our NPS test offerings are a testament to Aegis’ commitment to excellence and innovation. We continue to provide solutions that assist providers improve clinical care and prevent adverse outcomes. Current testing options include the following parent drugs and/or metabolites.

DESIGNER
OPIOIDS
  DESIGNER
BENZODIAZEPINES
  SYNTHETIC
STIMULANTS
  SYNTHETIC
CANNABINOIDS
2-Furanyl Fentanyl*   Adinazolam   2-Fluoroamphetamine   4-CN-CUMYL-BUTINACA
2-Furanylbenzyl Fentanyl*   Bromazolam   2-Fluoroethamphetamine   4F-MDMB-BUTICA
2-Methyl AP-237   Clonazolam   2-Fluoromethamphetamine   4F-MDMB-BUTINACA
Acryl Fentanyl   Deschloroetizolam   2-Methoxyamphetamine   5Cl-AKB48
Benzoyl Fentanyl*   Diclazepam   2-Methoxymethamphetamine   5F-AMB
Benzyl Fentanyl   Etizolam   3-Fluorophenmetrazine   5F-CUMYL-PINACA
Bromo Fentanyl   Flualprazolam   3/4-Fluoroamphetamine   5F-EDMB-PICA
Brorphine   Flubromazepam   3/4-Fluoroethamphetamine   5F-EDMB-PINACA*
Butyryl Fentanyl*   Flubromazolam   3/4-Fluoromethamphetamine   5F-MDMB-PICA/5F-EMB-PICA
Chloro Fentanyl   Flunitrazolam   4Cl-Alpha-PVP*   5F-MDMB-PINACA
Cyclopropyl Fentanyl*   Methylclonazepam   4-Fluoromethylphenidate   5F-NPB-22*
Desnitroisotonitazene   Nitrazolam*   Alpha-PiHP   5F-AB-PINACA
Despropionyl Fluorofentanyl   Phenazepam   Alpha-PHP   5F-PB-22
Etazene   Pyrazolam*   Alpha-PVP   AB-CHMINACA
Etonitazene       5/6-APB   AB-FUBINACA 
Fluoro Fentanyl  

HALLUCINOGENS/
DISSOCIATIVES

  Benzylone   Adamantyl-CHMINACA*
Fluorofuranyl Fentanyl   1cP-LSD   Butylone   ADB-FUBINACA*
Fluoroisobutyryl Fentanyl   1P-LSD   Chloro-N,N-DMC   ADB-PINACA
Isotonitazene   2C-B   Dibutylone*   APP-BINACA*
Methyl Fentanyl*   2F-Deschloroketamine   Ethylone*   EMB-FUBINACA
Metodesnitazene   3F-PCP   Eutylone   FUB-144*
Metonitazene   3/4F-Deschloroketamine   Methoxetamine*   FUB-AKB48*
Norcarfentanil   4-OH-DET*   p-Methoxyamphetamine   FUB-AMB*
Protonitazene   4-OH-DiPT*   p-Methoxymethamphetamine   FUB-PB-22
U-47700   4-OH-MET*   Methylone*   JWH-018*
U-48800*   25B-NBOH   N-butyl Hexedrone   JWH-073*
U-49900   25E-NBOH   N-butyl Pentylone*   JWH-250*
Valeryl Fentanyl   AL-LAD   N-ethyl Heptedrone   MAB-CHMINACA*
    ALD-52   N-ethyl Hexedrone*   MDMB-4en-PINACA
OTHER   Deschloroketamine   N-ethyl Pentedrone   MDMB-FUBICA*
Phenibut   Deschloro-N-Ethylketamine   N-ethyl Pentylone*   MDMB-FUBINACA*
Tianeptine   Methoxy PCP   Pentylone   MMB-4en-PICA
Xylazine       TFMPP   MMB-4en-PINACA
            MMB-FUBICA

 * - Indicates Urine Only

A complete and up to date list of the analytes contained in each listed drug class can be found at: www.aegislabs.com/Paincompthresholds*Parent drug listed for informational purposes only and not included in testing. Analytes listed for each drug class are current as of April 5, 2021. Updates and enhancements to the drug classes are made from time to time.


Recorded Webinars Available:



If you are a Healthcare Provider seeking information please contact your Regional Sales Manager or Client Services team at 1.800.533.7052 or email Client.Services@aegislabs.com